Johnson & Johnson has achieved its 64th consecutive year of dividend increases, raising its quarterly dividend by 3.1% to $1.34 per share in 2026. Despite strong overall sales growth driven by new drugs like Tremfya and Darzalex, the company faces significant challenges including a 55.7% drop in Stelara sales due to biosimilar competition and a slowdown in its MedTech division. Litigation costs related to talc lawsuits remain a concern but are now more quantifiable. With a forward P/E of 21 and solid free cash flow guidance, J&J remains a potentially attractive investment, though investors should watch for developments in MedTech and ongoing litigation.
Johnson & Johnson shares are trading at USD 257.34 on Pluang as of Oct 07, 2026 20:42 WIB, showing a 1.00% increase for the day. The stock has a dividend yield of 2.1%, reflecting its long history of dividend growth. Pluang investors currently favor buying, with 90% of order activity on the platform directed to buy JNJ shares.
With market risks rising in October 2026, five elite dividend stocks in healthcare, consumer staples, and utilities are highlighted for their resilience during downturns. These stocks, including Coca-Cola, Johnson & Johnson, McDonald's, NextEra Energ...
Procter & Gamble leads with 70 years of consecutive dividend increases, joined by Johnson & Johnson, Coca-Cola, ADP, and Lowe's, each maintaining solid payout ratios and strong cash flow coverage. These companies demonstrate resilience through recess...
Johnson & Johnson and Procter & Gamble are both Dividend Kings with similar valuations, but Johnson & Johnson is favored for long-term dividend growth due to better dividend coverage, lower payout ratio, and stronger growth prospects despite P&G's lo...
